WebbI was born and raised in Portugal and pursued my academic studies in the Biology field - a BSc in Molecular Biology and Genetics and an MSc in Human Biology and Environment. My first working experience was in the Uniked Kingdom, as a Laboratory Technician at a Genetic Toxicology CRO. Currently I'm working as a Quality Control Technician at a … WebbShouTi CEO Dr. Stevens pioneered the area of high-throughput structure-based drug discovery, founding multiple successful biotech companies including Syrrx, which developed the type 2 diabetes drug Nesina®, and Receptos, which developed Zeposia® — a GPCR targeted drug recently approved for multiple sclerosis and ulcerative colitis.
ShouTi Strengthens Board With Appointment of Daniel G. Welch …
Webb20 okt. 2024 · ShouTi Inc. is combining what science already knows about the structure of a key target for drugs with data on cell signaling to design small-molecule drugs that could ease the uptake of... Webb20 jan. 2024 · Accomplished biotechnology executive brings over 40 years of commercial and leadership experience across multinational pharmaceutical and biotechnology companies to ShouTi. SAN FRANCISCO & SHANGHAI ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule … china investing in african countries
ShouTi Strengthens Board With Appointment of Daniel G. Welch …
WebbDr. Ma has more than 15 years of research, technology, and drug discovery experience in pharma and biotech settings. Prior to joining ShouTi, Dr. Ma was site head and General … Webb29 okt. 2024 · SAN FRANCISCO & SHANGHAI-- ( BUSINESS WIRE )-- ShouTi Inc., a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF). Webb17 feb. 2024 · Having been used to navigating the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face … china invest in iran